jdemar
Guest
One of my Drs is taking the patient to the OR to inject platlet rich gel into the Achilles Tendon.....does anyone have any knowledge of this procedure??? :
-
If this is your first visit, be sure to check out the FAQ & read the forum rules. To view all forums, post or create a new thread, you must be an AAPC Member. If you are a member and have already registered for member area and forum access, you can log in by clicking here. If you've forgotten your username or password use our password reminder tool. To start viewing messages, select the forum that you want to visit from the selection below..
Wiki Platlet rich gel injection.
- Thread starter jdemar
- Start date
amitjoshi4
Guru
- Messages
- 113
- Best answers
- 0
Platelet rich gel injection
See this guideline:
“If physician draws patient's blood intraoperatively, uses special equipment in the OR to centrifuge into separate elements, isolation of the required component (red cells or platelets), and finally injecting the desired component into the operative site. With all this being well documented in a report, this would be captured with CPT code 86999*.”
I have been coding these procedures for quite a long time now .
Thank You
See this guideline:
“If physician draws patient's blood intraoperatively, uses special equipment in the OR to centrifuge into separate elements, isolation of the required component (red cells or platelets), and finally injecting the desired component into the operative site. With all this being well documented in a report, this would be captured with CPT code 86999*.”
I have been coding these procedures for quite a long time now .
Thank You
jdemar
Guest
Thank you both for your help, I am checking w my Dr. to see if the 86999 is correct, not sure if he is spinning the blood in the OR or the blood bank @ the hospital is taking care of that portion....thanks again
sgoodknight
Networker
20926 is the code that we use and we have been doing this for over a year. We are using the GPS from Biomet? Is this the same product you are using?
mdevereaux
New
- Messages
- 3
- Best answers
- 0
The code I was told to use by the rep is
36513: therapeutic apheresis;for platelets.
Apheresis: Medicine/Medical. the withdrawal of whole blood from the body, separation of one or more components, and return by transfusion of remaining blood to the donor
Mollie
36513: therapeutic apheresis;for platelets.
Apheresis: Medicine/Medical. the withdrawal of whole blood from the body, separation of one or more components, and return by transfusion of remaining blood to the donor
Mollie
mbort
True Blue
See this guideline:
“If physician draws patient's blood intraoperatively, uses special equipment in the OR to centrifuge into separate elements, isolation of the required component (red cells or platelets), and finally injecting the desired component into the operative site. With all this being well documented in a report, this would be captured with CPT code 86999*.”
I have been coding these procedures for quite a long time now .
Thank You
Where did this guideline come from?
amitjoshi4
Guru
- Messages
- 113
- Best answers
- 0
Hi,
This is the Q&A published in CPT Assistant "November 2005, Volume 15,Issue 11,Page 14"
Hope this benefits all.
Thank You
This is the Q&A published in CPT Assistant "November 2005, Volume 15,Issue 11,Page 14"
Hope this benefits all.
Thank You
mbort
True Blue
Since that CPT asst is from 2005, I think I will stick with Mollie. I also use the 36513. The lay description (which I have posted below) better describes what is performed.
36513
Therapeutic apheresis is the removal of some specific circulating blood component, cells or plasma solute, that is directly responsible for a disease process. Cells and plasma components may also be mobilized from other tissue storage during apheresis, such the from the spleen and lymph nodes, for enhanced clearance of the undesired element. The patient is prepared much the same as giving a regular blood donation. Whole blood is drawn out of one arm and into an instrument called a separator, which uses a microprocessing technique to draw the blood, anticoagulate it, and separate the component to be removed by centrifugal spinning, filtration, or column adsorption with the help of computerized calibration. The cells to be removed are collected while the remainder of the blood is recombined and returned to the patient through a tube and needle in the other arm. Report 36511 for white blood cell isolation and removal (leukapheresis or lymphocytapheresis), 36512 for red blood cell removal, and 36513 for removal of platelets.
36513
Therapeutic apheresis is the removal of some specific circulating blood component, cells or plasma solute, that is directly responsible for a disease process. Cells and plasma components may also be mobilized from other tissue storage during apheresis, such the from the spleen and lymph nodes, for enhanced clearance of the undesired element. The patient is prepared much the same as giving a regular blood donation. Whole blood is drawn out of one arm and into an instrument called a separator, which uses a microprocessing technique to draw the blood, anticoagulate it, and separate the component to be removed by centrifugal spinning, filtration, or column adsorption with the help of computerized calibration. The cells to be removed are collected while the remainder of the blood is recombined and returned to the patient through a tube and needle in the other arm. Report 36511 for white blood cell isolation and removal (leukapheresis or lymphocytapheresis), 36512 for red blood cell removal, and 36513 for removal of platelets.
judithdoss
Guest
Platelet rich gel injection
We also are doing the GPS, and have been billing for the injection(20550) and the graft(20926). However, in the April 2008 Ortho Pink Sheet it states that "there is no appropriate physician code to report". You may report 86999 if "you own or lease you own laboratory". I also listened to a audio conference on 6/10/08 given by Destiny Health( Margie Vaught) who states you can bill for the injection with a modifier 22 for the extra work. Hope this helps!
Judy
We also are doing the GPS, and have been billing for the injection(20550) and the graft(20926). However, in the April 2008 Ortho Pink Sheet it states that "there is no appropriate physician code to report". You may report 86999 if "you own or lease you own laboratory". I also listened to a audio conference on 6/10/08 given by Destiny Health( Margie Vaught) who states you can bill for the injection with a modifier 22 for the extra work. Hope this helps!
Judy
platelet rich injections
Below is the National Policy and there are many many LCDs with this also:
270.3 - Blood-Derived Products for Chronic Non-Healing Wounds - (Various Effective Dates Below)
(Rev. 83, Issued: 05-02-08, Effective: 03-19-08, Implementation: 06-02-08)
A. General
Wound healing is a dynamic, interactive process that involves multiple cells and proteins. There are three progressive stages of normal wound healing, and the typical wound healing duration is about 4 weeks. While cutaneous wounds are a disruption of the normal, anatomic structure and function of the skin, subcutaneous wounds involve tissue below the skin's surface. Wounds are categorized as either acute, in where the normal wound healing stages are not yet completed but it is presumed they will be, resulting in orderly and timely wound repair, or chronic, in where a wound has failed to progress through the normal wound healing stages and repair itself within a sufficient time period.
Platelet-rich plasma (PRP) is produced in an autologous or homologous manner. Autologous PRP is comprised of blood from the patient who will ultimately receive the PRP. Alternatively, homologous PRP is derived from blood from multiple donors.
Blood is donated by the patient and centrifuged to produce an autologous gel for treatment of chronic, non-healing cutaneous wounds that persists for 30 days or longer and fail to properly complete the healing process. Autologous blood derived products for chronic, non-healing wounds includes both: (1) platelet derived growth factor (PDGF) products (such as Procuren), and (2) PRP.
The PRP is different from previous products in that it contains whole cells including white cells, red cells, plasma, platelets, fibrinogen, stem cells, macrophages, and fibroblasts.
The PRP is used by physicians in clinical settings in treating chronic, non-healing wounds, open, cutaneous wounds, soft tissue, and bone. Alternatively, PDGF does not contain cells and was previously marketed as a product to be used by patients at home.
B. Nationally Covered Indications
Not applicable.
C. Nationally Non-Covered Indications
1. Effective December 28, 1992, the Centers for Medicare & Medicaid Services (CMS) issued a national non-coverage determination for platelet-derived wound-healing formulas intended to treat patients with chronic, non-healing wounds. This decision was based on a lack of sufficient published data to determine safety and efficacy, and a public health service technology assessment.
2. Effective July 23, 2004, upon reconsideration, the clinical effectiveness of autologous PDGF products continues to not be adequately proven in scientific literature. As the evidence is insufficient to conclude that autologous PDGF in a platelet-poor plasma is reasonable and necessary, it remains non-covered for treatment of chronic, non-healing cutaneous wounds. Also, the clinical evidence does not support a benefit in the application of autologous PRP for the treatment of chronic, non-healing, cutaneous wounds. Therefore, CMS determines it is not reasonable and necessary and is nationally non-covered.
3. Effective April 27, 2006, coverage for treatments utilizing becaplermin, a non-autologous growth factor for chronic, non-healing subcutaneous wounds, remains nationally non-covered under Part B based on section 1861(s)(2)(A) and (B) of the Social Security Act because this product is usually administered by the patient.
4. Effective March 19, 2008, upon reconsideration, the evidence is not adequate to conclude that autologous PRP is reasonable and necessary and remains non-covered for the treatment of chronic non-healing, cutaneous wounds. Additionally, upon reconsideration, the evidence is not adequate to conclude that autologous PRP is reasonable and necessary for the treatment of acute surgical wounds when the autologous PRP is applied directly to the closed incision, or for dehiscent wounds.
D. Other
In accordance with section 310.1 of the National Coverage Determinations Manual, the routine costs in Federally sponsored or approved clinical trials assessing the efficacy of autologous PRP in treating chronic, non-healing cutaneous wounds are covered by Medicare.
(This NCD last reviewed March 2008.)
CPT Adds their comments on PRP
CPT® Assistant November 2005 Volume 15 issue 11
"Question: During an orthopedic procedure, 60 cc of the patient's blood was drawn and then centrifuged for 15 minutes to separate the PLATELET-rich PLASMA from the PLATELET-poor PLASMA. The red cells were injected into the operative site. What are the appropriate CPT codes to report for these procedures?
AMA Comment: The instillation of the PLATELETs by the surgeon into the surgical site would not warrant additional CPT code reporting as this is considered an integral part of the total procedure performed; therefore, the instillation is not separately reportable as there is no significant, additional physician work involved. However, code 86999, Unlisted transfusion medicine procedure, should be reported when blood is drawn intraoperatively from the patient and centrifuged to separate the PLATELET-rich from PLATELET-poor PLASMA and the red cells are injected into the operative site."
Margie Scalley Vaught, CPC, CPC-H, CCS-P, MCS-P, ACS-EM, ACS-OR
Healthcare Consultant
Coding Content Specialist for DecisionHealth
scalley123@aol.com
cell 360-880-8304
fax 413-674-7668
www.margievaught.com
for workshops and audio http://www.margievaught.com/calendar/index.cfm
Below is the National Policy and there are many many LCDs with this also:
270.3 - Blood-Derived Products for Chronic Non-Healing Wounds - (Various Effective Dates Below)
(Rev. 83, Issued: 05-02-08, Effective: 03-19-08, Implementation: 06-02-08)
A. General
Wound healing is a dynamic, interactive process that involves multiple cells and proteins. There are three progressive stages of normal wound healing, and the typical wound healing duration is about 4 weeks. While cutaneous wounds are a disruption of the normal, anatomic structure and function of the skin, subcutaneous wounds involve tissue below the skin's surface. Wounds are categorized as either acute, in where the normal wound healing stages are not yet completed but it is presumed they will be, resulting in orderly and timely wound repair, or chronic, in where a wound has failed to progress through the normal wound healing stages and repair itself within a sufficient time period.
Platelet-rich plasma (PRP) is produced in an autologous or homologous manner. Autologous PRP is comprised of blood from the patient who will ultimately receive the PRP. Alternatively, homologous PRP is derived from blood from multiple donors.
Blood is donated by the patient and centrifuged to produce an autologous gel for treatment of chronic, non-healing cutaneous wounds that persists for 30 days or longer and fail to properly complete the healing process. Autologous blood derived products for chronic, non-healing wounds includes both: (1) platelet derived growth factor (PDGF) products (such as Procuren), and (2) PRP.
The PRP is different from previous products in that it contains whole cells including white cells, red cells, plasma, platelets, fibrinogen, stem cells, macrophages, and fibroblasts.
The PRP is used by physicians in clinical settings in treating chronic, non-healing wounds, open, cutaneous wounds, soft tissue, and bone. Alternatively, PDGF does not contain cells and was previously marketed as a product to be used by patients at home.
B. Nationally Covered Indications
Not applicable.
C. Nationally Non-Covered Indications
1. Effective December 28, 1992, the Centers for Medicare & Medicaid Services (CMS) issued a national non-coverage determination for platelet-derived wound-healing formulas intended to treat patients with chronic, non-healing wounds. This decision was based on a lack of sufficient published data to determine safety and efficacy, and a public health service technology assessment.
2. Effective July 23, 2004, upon reconsideration, the clinical effectiveness of autologous PDGF products continues to not be adequately proven in scientific literature. As the evidence is insufficient to conclude that autologous PDGF in a platelet-poor plasma is reasonable and necessary, it remains non-covered for treatment of chronic, non-healing cutaneous wounds. Also, the clinical evidence does not support a benefit in the application of autologous PRP for the treatment of chronic, non-healing, cutaneous wounds. Therefore, CMS determines it is not reasonable and necessary and is nationally non-covered.
3. Effective April 27, 2006, coverage for treatments utilizing becaplermin, a non-autologous growth factor for chronic, non-healing subcutaneous wounds, remains nationally non-covered under Part B based on section 1861(s)(2)(A) and (B) of the Social Security Act because this product is usually administered by the patient.
4. Effective March 19, 2008, upon reconsideration, the evidence is not adequate to conclude that autologous PRP is reasonable and necessary and remains non-covered for the treatment of chronic non-healing, cutaneous wounds. Additionally, upon reconsideration, the evidence is not adequate to conclude that autologous PRP is reasonable and necessary for the treatment of acute surgical wounds when the autologous PRP is applied directly to the closed incision, or for dehiscent wounds.
D. Other
In accordance with section 310.1 of the National Coverage Determinations Manual, the routine costs in Federally sponsored or approved clinical trials assessing the efficacy of autologous PRP in treating chronic, non-healing cutaneous wounds are covered by Medicare.
(This NCD last reviewed March 2008.)
CPT Adds their comments on PRP
CPT® Assistant November 2005 Volume 15 issue 11
"Question: During an orthopedic procedure, 60 cc of the patient's blood was drawn and then centrifuged for 15 minutes to separate the PLATELET-rich PLASMA from the PLATELET-poor PLASMA. The red cells were injected into the operative site. What are the appropriate CPT codes to report for these procedures?
AMA Comment: The instillation of the PLATELETs by the surgeon into the surgical site would not warrant additional CPT code reporting as this is considered an integral part of the total procedure performed; therefore, the instillation is not separately reportable as there is no significant, additional physician work involved. However, code 86999, Unlisted transfusion medicine procedure, should be reported when blood is drawn intraoperatively from the patient and centrifuged to separate the PLATELET-rich from PLATELET-poor PLASMA and the red cells are injected into the operative site."
Margie Scalley Vaught, CPC, CPC-H, CCS-P, MCS-P, ACS-EM, ACS-OR
Healthcare Consultant
Coding Content Specialist for DecisionHealth
scalley123@aol.com
cell 360-880-8304
fax 413-674-7668
www.margievaught.com
for workshops and audio http://www.margievaught.com/calendar/index.cfm